Rein Therapeutics
RNTX
20 hedge funds and large institutions have $652K invested in Rein Therapeutics in 2020 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
18% more funds holding
Funds holding: 17 → 20 (+3)
0.05% more ownership
Funds ownership: 0.3% → 0.35% (+0.05%)
32% less capital invested
Capital invested by funds: $957K → $652K (-$305K)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBVA
Banco Bilbao Vizcaya Argentaria
Madrid,
Spain
|
+$213K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$11.3K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$9.56K |
| 4 |
GPFA
Game Plan Financial Advisors
Westlake,
Ohio
|
+$7.23K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$4.12K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
-$26.6K |
| 2 |
JSMC
Jess S. Morgan & Co
Los Angeles,
California
|
-$15.1K |
| 3 |
PCS
Personal CFO Solutions
Chester,
New Jersey
|
-$8.43K |
| 4 |
Renaissance Technologies
New York
|
-$8.37K |
| 5 |
BlackRock
New York
|
-$7.56K |
RNTX Hedge Fund Activity: Q1 2020 in Review
20 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q1 2020, worth a combined $652K — down 32% from $957K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new RNTX positions and 1 closed out — a net gain of 3 holders — while 4 added to existing stakes and 6 trimmed.
The largest buyer was Banco Bilbao Vizcaya Argentaria, adding an estimated $213K. The largest seller was William Blair & Company, cutting an estimated $26.6K.
- 20 institutional investors held Rein Therapeutics (RNTX) as of Q1 2020, up from 17 in Q4 2019.
- Funds reported $652K of Rein Therapeutics stock for Q1 2020, down 32% quarter-over-quarter.
- 4 funds opened new Rein Therapeutics positions in Q1 2020 and 1 closed out, a net change of +3 holders.
- The largest Rein Therapeutics buyer in Q1 2020 was Banco Bilbao Vizcaya Argentaria, an estimated $213K added.
- The largest Rein Therapeutics seller in Q1 2020 was William Blair & Company, an estimated $26.6K sold.
Based on aggregated 13F filings for Q1 2020.